Mark Leibowitz

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients

Gilbert Lefèvre, G Sędek, S. S. Jhee et al. · Clinical Pharmacology & Therapeutics · 2007 · 126 citations · Full text

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 108 citations

Neurodegenerative Diseases, Neuropsychology, Alzheimer's Disease +11

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

John J. Sramek, Mark Leibowitz, Samuel Weinstein et al. · Journal of Human Hypertension · 2002 · 79 citations

Obesity, Metabolic Syndrome, Hypertension +12

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Katie Kompoliti, Charles H. Adler, Rema Raman et al. · Neurology · 2002 · 72 citations

Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

Carol Addy, C. Assaid, David Hreniuk et al. · The Journal of Clinical Pharmacology · 2009 · 61 citations

Nr2b‐selective Nmda Antagonist, Neurological Progress, Clinical Neuroscience +17